References
- Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J. Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells. Leuk Lymphoma 2009;50:667–669.
- Lora-Tamayo J, Palom X, Sarra J, et al Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin Lymphoma Myeloma 2008;8:363–369.
- Metzeler KH, Boeck S, Christ B, et al Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: case report and review of the literature. Leuk Res 2009;33:e69–e72.
- Ho AY, Mijovic A, Pagliuca A, Mufti GJ. Idiopathic hyperammonemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplant 1997;20:1007–1008.
- Kadowaki M, Kanazawa T. Amino acids as regulators of proteolysis. J Nutr 2003;133(Suppl. 1):2052S–2056S.
- Belanger M, Desjardins P, Chatauret N, Butterworth RF. Loss of expression of glial fibrillary acidic protein in acute hyperammonemia. Neurochem Int 2002;41:155–160.
- Talamo G, Cavallo F, Zangari M, et al Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol 2007;82:414–415.
- Fujii S, Fukuda S, Sezaki T, Murakami M. [Clinicopathological study of multiple myeloma associated with hyperammonemia]. Rinsho Ketsueki 1998;39:27–33.
- Otsuki T, Yamada O, Sakaguchi H, et al In vitro excess ammonia production in human myeloma cell lines. Leukemia 1998;12:1149–1158.
- Matsuzaki H, Matsuno F, Yoshida M, Hata H, Okazaki K, Takatsuki K. Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia. Intern Med 1992;31:339–343.
- Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004;104:802–809.
- Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007;20:701–715.
- Reeder CB, Reece DE, Kukreti V, et al Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337–1341.
- Reece DE, Rodriguez GP, Chen C, et al Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777–4783.
- Kenealy MK, Prince HM, Honemann D. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy 2006;26:1205–1206.